Tag Archive for 'Biotechnology and Pharmaceuticals'

Aastrom Reports Interim Results From Critical Limb Ischemia Trial

| Share
Published
by
Stem Man
on 25 February 2010
. 0 Comments

Aastrom Biosciences, Inc. (Nasdaq:ASTMD), a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported results from a planned interim analysis of the company’s multi-center, randomized, double-blind, placebo-controlled U.S. Phase 2b clinical trial designated RESTORE-CLI. According to the interim analysis the safety profile was similar between the treatment and placebo arms.

Based on a composite efficacy endpoint assessing time to treatment failure (including major amputations, wound size and gangrene), Aastrom’s autologous vascular repair cells (VRCs) were more effective than placebo (P<0.05). Other clinically meaningful endpoints (e.g., major amputation rate, complete wound closure) approached but did not reach statistical significance at interim analysis. Forty-six critical limb ischemia (CLI) patients who had at least 6-month follow up, including 33 patients with 12-month follow up, contributed to the interim analysis.

Continue reading ‘Aastrom Reports Interim Results From Critical Limb Ischemia Trial’

Maybe you can find something interesting in the following sponsored links:

Incoming search terms:

aastrom cli phase 1, einen tag blind experiment, outcome of critical limb ischemia, stem cell critical limb ischemia trial, stem cell therapy for critical limb ischemia.

PluristemBegins Enrollment in U.S. With Unmatched Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease

| Share
Published
by
Stem Man
on 10 September 2009
. 2 Comments

Pluristem Therapeutics Inc. today announced that it has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD, the Company`s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

Enrollment began at the Center for Therapeutic Angiogenesis in Birmingham, Ala., one of two clinical sites in the U.S. Duke University Medical Center will also be screening patients for the trial. The initiation of this study follows the approval of the Company`s Investigational New Drug (IND) application to begin clinical trials with PLX-PAD by the U.S. Food & Drug Administration (FDA). The Phase I study is designed to evaluate the safety of PLX-PAD in patients with CLI. A total of up to 12 adults with the disease will be included in this dose escalating trial (…)

from http://www.reuters.com/article/pressRelease/idUS125367+10-Sep-2009+BW20090910

Reblog this post [with Zemanta]

Incoming search terms:

Pluristem Therapeutics retinitis pigmentosa.

Share to Facebook Share to Twitter Stumble It Email This More...
Related pages on the web
  • Facts about Weight and Weight Loss Here are some little known facts about your weight, and how to lose it. - The difference between people who are thin and those who are obese is not how many fat cells they have, but rather the size of...
  • Kanji Sketch Pad v2.76 - Latest Trial Version of the Software Version 2.76 is ready for a trial. This is a significant update, because it introduces the kanji radical lookup feature. This feature is not quite finalised, and has the following known limitations: it is not suitable for small-screen users, and...
  • Male Bass in Numerous US Rivers Seem to Have Been Feminized According to Study Government scientists are figuring that one out of every five black bass in the American river basins, despite being male, have egg cells that are growing inside of their typical sex organs, and this is a sign of just how...
  • MonaVie is Trying to Sue Me... ... and I couldn't be happier about it. For those who don't know, MonaVie is a juice, that retails for $1.70 an ounce (yes ounce). Being the consumer advocate that I am, I wrote that I think MonaVie is a...
Blog Traffic Exchange Related articles on this site